This year’s BIO International Convention in the US saw the strongest ever participation from South Korea, with 544 companies from the relatively small country reportedly registered and the number of Korean attendees the second-largest after the US, despite overlapping events such as the American Society of Clinical Oncology meeting and Jefferies NY Healthcare conference.
Feeling The 'K-Bio' Partnering Fervor In Boston: PharmAbcine’s Story
World-First IND Approval
With Korea accounting for the second-highest number of attendees after the US this year, the BIO International Convention was crowded with biopharma firms from the country looking for partnerships. PharmAbcine CEO Jin-San Yoo shared his experience of the event and provides updates on key R&D programs including a unique TIE2 agonist antibody.
More from Sensory
• By
The company said the NORSE EIGHT trial of ONS-5010 did not meet the primary endpoint of showing noninferiority to ranibizumab, but it still plans to file for US FDA approval.
• By
But differences in trial design means it is hard to handicap GSK’s product against Mirum’s volixibat.
• By
The company is developing the drug as a way to reduce injection burden for wet AMD patients and plans to meet with the US FDA early next year to discuss Phase IIb topline results.
• By
The dual agonist of the FP and EP3 receptors has shown efficacy in a Japanese Phase III trial and completed its US Phase II study, which aligns with the Japanese firm’s global expansion strategy for glaucoma products.
More from Therapy Areas
• By
After a long wait for patients, Vykat has become the first drug approved for Prader-Willi syndrome symptoms, opening the market up for Soleno and future challengers.
• By
With its exon 53-skipping candidate already showing promise in 24-week data, Wave now has 48-week data showing improvements in muscle health and functional outcomes.
• By
J&J is confident that its bispecific antibody/kinase inhibitor combo’s overall survival win over AstraZeneca’s single-agent pill will shift the standard of care.